Clinical Trials Logo

Mental Disorders clinical trials

View clinical trials related to Mental Disorders.

Filter by:

NCT ID: NCT05039164 Enrolling by invitation - Behavior Disorders Clinical Trials

Evaluation of a Remote Training Strategy

Start date: September 20, 2022
Phase: N/A
Study type: Interventional

An increasing number of schools in rural settings are employing the multi-tier positive behavioral interventions and supports (PBIS) framework to improve school-climate. PBIS can also be used as a framework for the adoption and integration of evidence-based practices (EBPs) for children's mental health concerns. A key challenge is that school personnel need technical assistance (training plus ongoing consultation) in order to implement EBPs with fidelity. In urban and suburban schools, this support can be provided to school staff on site. However, providing ongoing on-site support is not feasible or sustainable in the majority of rural schools, due to their remote physical location. For this reason, video technology has been recommended for the training of behavioral health staff (BHS) in under-served rural communities.

NCT ID: NCT04869657 Enrolling by invitation - Behavior Disorders Clinical Trials

Sustainment of Mental Health Supports

Start date: September 17, 2021
Phase: N/A
Study type: Interventional

Schools are in great need of service delivery systems that can improve school climate and also attend to students' mental health. One effective approach is Positive Behavioral Interventions and Supports (PBIS), a multitiered framework for defining and organizing practices and interventions (including mental health practices).

NCT ID: NCT04635618 Enrolling by invitation - Depression Clinical Trials

Psychotherapy Strategies for the Treatment of Professionals and Students From Essential Services With High Levels of Emotional Distress in the Context of COVID-19

Start date: November 5, 2020
Phase: N/A
Study type: Interventional

The study consists in a pragmatic superiority randomized controlled trial comparing different strategies of psychotherapy for professionals and students from essential services with high levels of emotional distress during the COVID-19 pandemic in Brazil. Therapeutic strategies to be evaluated are Brief Cognitive Behavioral Telepsychotherapy, Brief Interpersonal Telepsychotherapy and Telepsychoeducation, as an active control. Note: This study was approved by the Ethics and Research Committee of the Hospital de Clínicas de Porto Alegre and is originally registered at Plataforma Brasil, a Brazilian study registration platform (under CAAE: 30608420.5.0000.5327). Recruitment began in May 28th 2020.

NCT ID: NCT04634175 Enrolling by invitation - Clinical trials for Compulsive Sexual Behavior

Mind-body Intervention for Compulsive Sexual Behavior Disorder

CSBD
Start date: July 15, 2021
Phase: N/A
Study type: Interventional

Mind-body intervention as a complementary and integrative treatment for compulsive sexual behavior disorder. The hypothesis is that participants with CSBD, after being submitted to the protocol of the mind-body intervention group in relation to those submitted to the intervention protocol Shan of the control group, present less severe sexual compulsiveness.

NCT ID: NCT04323566 Enrolling by invitation - Schizophrenia Clinical Trials

Rituximab Treatment for Psychosis and/or Obsessive Compulsive Disorder With Probable Immune System Involvement

Ra-P-OCD
Start date: May 1, 2022
Phase: Phase 2
Study type: Interventional

The primary objective for this study is to evaluate whether Rituximab as compared to placebo is a clinically effective treatment for a subgroup of patients suffering from psychosis and/or obsessive-compulsive disorder (OCD) or -behavior (OCB) where there is an indication of immune system involvement. The secondary objectives of this study are 1. To assess whether Rituximab treatment (with the doses and timing described below) as compared to placebo is associated with amelioration in psychiatric symptomatology 2. To assess whether Rituximab treatment as compared to placebo is associated with improvement in executive functions 3. To assess whether Rituximab treatment as compared to placebo is associated with amelioration in neurological symptoms 4. To evaluate the longevity of psychiatric, neurological and executive improvements associated with Rituximab treatment for up to 16 months after the first infusion (i.e. 12 months after the last infusion) 5. To evaluate whether Rituximab treatment as described is safe for these patients. The exploratory objectives of this study are 1. To assess changes in blood and cerebrospinal fluid (CSF) markers for immune activity associated with Rituximab treatment compared to placebo 2. To assess statistical associations between biological markers in blood or CSF and clinical response 3. To describe changes in somatic symptoms associated with treatment with Rituximab vs placebo for patients with initial symptoms in the questionnaires 4. To describe changes on MR and EEG associated with treatment with Rituximab vs placebo for patients with initial pathology in these examination 5. To study immune mechanisms coupled with psychiatric symptoms, possibly identifying novel biomarkers with potential for subtyping encephalopathies with immune engagement, using biobank cells, blood and CSF samples collected from the participants.

NCT ID: NCT04290650 Enrolling by invitation - Sleep Disturbance Clinical Trials

Sleep Disturbances in Patients With Psychotic Symptoms (AkuSleep)

AkuSleep
Start date: September 1, 2020
Phase: N/A
Study type: Interventional

Sleep disturbance is recognized as a major problem for patients with psychosis and is seen in nearly all patients admitted in acute crisis to a psychiatric hospital. Cognitive behavioral treatment is recommended as first-line treatment for insomnia in national and international guidelines. This study explores effect of adapting the milieu therapy to comply with the principles of CBT for insomnia. Our aim is to rethink our day to day psychological interventions and our around the clock milieu therapy for patients with acute and severe mental illness in light of established knowledge on how sleep is obtained and maintained.

NCT ID: NCT04218968 Enrolling by invitation - Clinical trials for REM Sleep Behavior Disorder

Cardiac Changes in Early Parkinson's Disease: A Follow up Study

Start date: December 30, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the long-term effects of treatment with the adrenergic blocker carvedilol on serial DaTscan, a dopamine transporter (DAT) single photon emission computerized tomography (SPECT) imaging technique in a population of subjects with defined pre-motor Parkinson's disease risks (i.e., REM sleep Behavior Disorder (RBD) and at least one among hyposmia, constipation, depression and color vision abnormality) and abnormal 123I-Metaiodobenzylguanidine (MIBG) scintigraphy.

NCT ID: NCT04156373 Enrolling by invitation - Clinical trials for Trauma, Psychological

Fuerte Program for Newcomer Immigrant Youth

Fuerte
Start date: November 23, 2020
Phase: N/A
Study type: Interventional

The present study is a randomized control trial to evaluate the efficacy and effectiveness of a school-based group prevention program (Fuerte) in San Francisco Unified School District Public Schools. In addition, the present study will also inform effective procedures for adaptations of the Fuerte program for other newcomer immigrant youth from non-Latin American countries. Fuerte targets newcomer Latinx immigrant youth (five years or less post arrival in the U.S.) who are at risk of experiencing traumatic stress. In particular, the Fuerte program focuses on increasing youth's mental health literacy, improving their social functioning, and identifying and connecting at-risk youth to specialty mental health services. The program will be implemented by mental health providers from various county community-based organizations, as well as from the SFUSD Wellness Centers, who already offer mental health services in SFUSD schools.

NCT ID: NCT04007510 Enrolling by invitation - Clinical trials for First Episode Psychosis (FEP)

California Collaborative Network to Promote Data Driven Care and Improve Outcomes in Early Psychosis

EPI-CAL
Start date: September 10, 2019
Phase: N/A
Study type: Interventional

The proposed project seeks to create a California early psychosis network using a core assessment battery of valid, low burden measures and mHealth technology platform to collect client-level data, visualize data via clinician dashboard for treatment planning, and integrate across clinics to provide de-identified data to the national coordinating hub. Research capacity for the network will be tested via development and validation of a measure of the Duration of Untreated Psychosis (DUP) that is feasible for use in community settings. The proposed California network will contribute systematically collected outcomes data on over 100 FEP clients per year, from 12 community and university EP clinics, to enhance the development of a national EP network, supported by the NIMH EPINET program.

NCT ID: NCT03970005 Enrolling by invitation - Clinical trials for Prodromal Schizophrenia

Evaluation of Step-Based Care for Individuals at Clinical High Risk for Psychosis

Start date: April 19, 2019
Phase:
Study type: Observational [Patient Registry]

The Ohio State University Early Psychosis Intervention Center is implementing a specialized clinical program to serve individuals who meet clinical high risk criteria for a psychosis. The purpose of this study is to evaluate the long-term outcomes among individuals participating in this clinical service.